 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...1314151617181920212223...4950» |
- Tecentriq (atezolizumab) / Roche
neoMono - An adaptive randomized neoadjuvant two arm trial in patients with TNBC comparing a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_345;
Up to four planned efficacy interim analyses provide decision points for early stopping for success or futility. The expected maximum number of patients to be recruited is 458.
- docetaxel / Generic mfg., epirubicin / Generic mfg.
Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_67;
However, concerns about the increased risks of cardiac toxicity and leukaemia with anthracyclines have resulted in wider use of taxane chemotherapy schedules without anthracycline, in particular docetaxel-cyclophosphamide (DC)...The proportional reduction in recurrence was greatest in trials of concurrent Anth + DC versus DC (RR 0.66, 95%CI 0.55-0.79; p0.1... The addition of anthracycline to taxane chemotherapy, compared to taxane alone reduced the risk of breast cancer recurrence by 18% with larger proportional reductions in trials of DC ± concurrent Anth, in which the taxane dose was the same in both groups and the cumulative anthracycline dose was higher.
- Keytruda (pembrolizumab) / Merck (MSD)
KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC) (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_3;
P3
EFS sensitivity analyses show a robust treatment benefit of neoadjuvant pembro + chemo followed by adjuvant pembro for previously untreated non-metastatic TNBC. This benefit was generally consistent across a broad selection of patient subgroups.
- || pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I-III Breast Cancer. (Pubmed Central) - Oct 8, 2021
Based on the large sample size and the long follow-up time of this study, we conclude that PLD has a similar anti-breast cancer efficacy as epirubicin while inducing lower level of cardiac toxicity in Han Chinese. This study suggests that PLD-based adjuvant chemotherapy could be a better option than epirubicin for breast cancer patients especially with existing cardiac disease.
- || epirubicin / Generic mfg.
Clinical, Observational data, Journal: Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients. (Pubmed Central) - Oct 8, 2021
The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA. These results contribute more accurate information provision and insights regarding the proper treatment of CIA.
- zolbetuximab (IMAB362) / Astellas
SPOTLIGHT: Phase 3 study of Zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1094;
P2, P3
Introduction: Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase 2 (NCT01630083) results showed prolonged survival of patients with CLDN18.2+ advanced G/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...Other secondary endpoints are objective response rate, duration of response, safety/tolerability, pharmacokinetics, and immunogenicity of zolbetuximab. As of April 2021, 165 sites were open for screening and enrollment.
- | epirubicin / Generic mfg.
Journal: Epirubicin-induced Kounis syndrome. (Pubmed Central) - Oct 6, 2021
This case is the first to suggest that an intraarterial epirubicin injection could potentially be one of its triggers. All physicians should be aware of the pathophysiology of this condition to better recognize it and start appropriate treatment; this will prevent aggravation of the vasospastic cardiac attacks and yield a better outcome.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] KEYNOTE-522: Phase 3 Study of Neoadjuvant Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab Versus Placebo for Early-Stage Triple-Negative Breast Cancer (TNBC) (Channel 5) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_2070;
P3
Patients with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to neoadjuvant pembrolizumab 200 mg Q3W or placebo, both given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide. Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab showed a statistically significant and clinically meaningful improvement in EFS compared with neoadjuvant chemotherapy alone in patients with early-stage TNBC.
- | paclitaxel / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis. (Pubmed Central) - Oct 2, 2021
No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19-1.81, p = 0.35; HR: 0.58; 95% CI: 0.19-1.81, p = 0.35, respectively). In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.
- | epirubicin / Generic mfg.
Journal: Potential hepatoprotective effects of flavonoids contained in propolis from South Sulawesi against chemotherapy agents. (Pubmed Central) - Oct 1, 2021
In this study, total polyphenol and flavonoid tests of propolis have been carried out, there were 1.1% polyphenols and 2.7% flavonoids, the antioxidant activity tests showed IC50 value of 9849 ppm and LCMS/MS tests supported the presence of phenolic compounds in propolis from South Sulawesi. Liver parameter was measured and the results showed that the propolis 200 mg/kg group produced the lowest ALT and had potential protective effect against doxorubicin and epirubicin-induced hepatotoxicity.
- | epirubicin / Generic mfg.
Journal: MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway. (Pubmed Central) - Oct 1, 2021
MEDAG regulates BC progression and EMT via the AKT/AMPK/mTOR pathway and reduces chemosensitivity in BC cells. Therefore, MEDAG is a promising target for BC.
- || Herceptin (trastuzumab) / Roche, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical data, Observational data, Retrospective data, Journal: Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study. (Pubmed Central) - Sep 30, 2021
Among the taxanes, conventional paclitaxel (PTX) and docetaxel have usually been adopted in the neoadjuvant or adjuvant setting...In this study, 50 patients with primary breast cancer received nab-PTX (q3w, 260 mg/m ± trastuzumab 6 mg/kg) followed by FEC (q3w, 5-fluorouracil 500 mg/m, epirubicin 100 mg/m, and cyclophosphamide 500 mg/m) prior to surgery...The safety profiles were comparable with previously reported regimens, and high RDIs were obtained (97.2% for nab-PTX and 95.5% for FEC). This study illustrated the efficacy and tolerability of a neoadjuvant regimen of nab-PTX followed by FEC.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. (Pubmed Central) - Sep 29, 2021
P2
It may provide new insight in prevention of cardiotoxicity in patients receiving adjuvant or neo-adjuvant therapy containing anthracyclines. Furthermore, it may enable identification of patients at higher risk of developing cardiotoxicity and identification of those most likely to respond to cardioprotective therapy.
- || cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, HEOR: Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer. (Pubmed Central) - Sep 26, 2021
GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment.
- | epirubicin / Generic mfg.
Journal: EphA2 promotes tumorigenicity of cervical cancer by up-regulating CDK6. (Pubmed Central) - Sep 25, 2021
Inhibition of EphA2 by AWL-II-41-27, EphA2-specific tyrosine kinase inhibitor, or knock-down of EphA2 decreased mRNA and protein expression of cyclin-dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti-cancer chemotherapy drug...EphA2 protein expression was positively correlated with CDK6 protein expression, invasion depth, lymph node metastasis and clinicopathological stage (P < .05). This study demonstrates the oncogenic activity of EphA2 in vitro and in vivo, which provides insights into the relevant mechanisms that might lead to novel treatments for CC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 24, 2021
P2, N=54, Enrolling by invitation, Sponsor: Shanghai Zhongshan Hospital
This study demonstrates the oncogenic activity of EphA2 in vitro and in vivo, which provides insights into the relevant mechanisms that might lead to novel treatments for CC. Not yet recruiting --> Enrolling by invitation
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly
Trial completion date, Trial primary completion date: Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. (clinicaltrials.gov) - Sep 23, 2021
P1, N=45, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Enrolling by invitation Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Sep 23, 2021
P2, N=40, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Active, not recruiting --> Completed
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PREDIX II HER2: Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (clinicaltrials.gov) - Sep 23, 2021
P2, N=6, Terminated, Sponsor: Renske Altena
Active, not recruiting --> Completed N=190 --> 6 | Trial completion date: Dec 2034 --> Jun 2021 | Suspended --> Terminated | Trial primary completion date: Dec 2024 --> Jun 2021; Security and effect data from another ongoing study.
- | epirubicin / Generic mfg., idarubicin hydrochloride / Generic mfg.
New trial: Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 22, 2021
P=N/A, N=186, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- || epirubicin / Generic mfg.
Clinical, Journal: Chemometric Analysis of UV-Visible Spectral Fingerprints for the Discrimination and Quantification of Clinical Anthracycline Drug Preparation Used in Oncology. (Pubmed Central) - Sep 22, 2021
The use of partial least square regression PLS shows high quantification performance of these molecules in solution represented by the low value of root mean square error of calibration (RMSEC) and root mean square error of cross validation (RMSCECV) on the one hand and the high value of R-square on the other hand. This study demonstrated the viability of UV-visible fingerprinting (routine approach) coupled with chemometric tools for the classification and quantification of chemotherapeutic drugs during clinical preparation.
- | Nexavar (sorafenib) / Bayer, Amgen
Preclinical, Journal: Oxymestane, a Cytostatic Steroid Derivative of Exemestane with Greater Antitumor Activity in Non-Estrogen-Dependent Cell Lines. (Pubmed Central) - Sep 22, 2021
The results obtained allow concluding that Oxy can be a promising anticancer agent to be used in chemotherapy protocols. Furthermore, its ability to inhibit crucial components of DDR can also be useful for the monotherapy or for combination with chemo and/or radiotherapy of cancer.
- || Tomudex (raltitrexed) / Pfizer, AstraZeneca
Clinical, Journal: The short-term efficacy of DEB-TACE loaded with epirubicin and raltitrexed in the treatment of intermediate and advanced primary hepatocellular carcinoma. (Pubmed Central) - Sep 21, 2021
Furthermore, its ability to inhibit crucial components of DDR can also be useful for the monotherapy or for combination with chemo and/or radiotherapy of cancer. DEB-TACE loaded with epirubicin and raltitrexed improves the short-term outcomes, reduces the tumor load, decreases the incidence of adverse events, and improves the survival rate in patients with intermediate and advanced PHC.
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial suspension, Surgery: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (clinicaltrials.gov) - Sep 21, 2021
P2, N=60, Suspended, Sponsor: Rutgers, The State University of New Jersey
DEB-TACE loaded with epirubicin and raltitrexed improves the short-term outcomes, reduces the tumor load, decreases the incidence of adverse events, and improves the survival rate in patients with intermediate and advanced PHC. Recruiting --> Suspended
- ||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Sep 20, 2021
P3, N=1846, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Active, not recruiting --> Completed
- | epirubicin / Generic mfg.
Journal: Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study. (Pubmed Central) - Sep 19, 2021
Our overall prediction findings indicate that Epirubicin, Vapreotida, and Saquinavir may inhibit COVID-19 by synergistic interactions in the active cavity and those results can pave the way in drug discovery although it has to be further validated by in-vitro and in-vivo investigations. Communicated by Ramaswamy H. Sarma.
- || epirubicin / Generic mfg.
Clinical, Journal: Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. (Pubmed Central) - Sep 19, 2021
P2
Despite late consequences of Nab-Pac cannot be ruled out, these data suggest that different chemotherapeutics might have distinct effects on the immune cell repertoire and that different immune cell populations exhibit a specific susceptibility to these chemotherapies with B and NK cells being more affected than T cells. This might also have an impact on the combination of chemotherapies with immunotherapies.
- | epirubicin / Generic mfg.
Journal: Tissue distribution of epirubicin after severe extravasation in humans. (Pubmed Central) - Sep 19, 2021
Surgical intervention after demarcation of the extravasation lesion allows for almost uninterrupted continuation of treatment independent of the amount of extravasated anthracycline. As even minor amounts of the vesicants may trigger tissue necrosis, preventive measures merit the highest priority.
- | Zepsun (donafenib) / Suzhou Zelgen
Preclinical, Journal: Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8 T-Cell Infiltration in Rabbit VX2 Liver Tumor. (Pubmed Central) - Sep 16, 2021
The combination of TAE and angiogenesis inhibitor donafenib resulted in a potentiated tumoricidal effect, anti-angiogenesis and antitumour T cell response in rabbit VX2 liver tumor model. This may provide a potential basis for exploring the immune-related mechanisms of embolization in liver cancer.
- | epirubicin / Generic mfg.
Biomarker, Journal: Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. (Pubmed Central) - Sep 15, 2021
Although limited to a pilot study, these findings suggest that periostin might contribute prognostic information in LMS, MFS and UPS. Moreover, a transitioning EMT score measured in the tumor might predict a less active and a more chemosensitive disease.
- | epirubicin / Generic mfg.
Preclinical, Journal: Effects of Oleuropein on Epirubicin and Cyclophosphamide Combination Treatment in Rats (Pubmed Central) - Sep 10, 2021
Oleuropein might be a beneficial agent against toxicity caused by the combination treatment of cyclophosphamide and epirubicin. Further studies should be performed to demonstrate the protective effects of oleuropein against antineoplastic induced-toxicity precisely.
- Herceptin (trastuzumab) / Roche
Trial termination, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Sep 10, 2021
P2, N=7, Terminated, Sponsor: Washington University School of Medicine
Further studies should be performed to demonstrate the protective effects of oleuropein against antineoplastic induced-toxicity precisely. Active, not recruiting --> Terminated; Loss of study funding
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal, Combination therapy: Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma. (Pubmed Central) - Sep 5, 2021
Active, not recruiting --> Terminated; Loss of study funding High-dose anlotinib combined with epirubicin was an effective and safe therapy for STS.
- || digoxin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: The Effective Use of Digoxin in a Patient with Metastatic Breast Cancer and Anthracycline-induced Cardiomyopathy. (Pubmed Central) - Sep 5, 2021
Pimobendan was discontinued because of ventricular arrhythmia and hypotension. After the start of low-dose (0.125 mg daily) digoxin, her LVEF increased to 42%, and her HF symptoms improved with no adverse events.
- | epirubicin / Generic mfg.
New P2 trial: EPOS-1: Epirubicin for the Treatment of Sepsis & Septic Shock (clinicaltrials.gov) - Sep 5, 2021
P2, N=45, Not yet recruiting, Sponsor: Jena University Hospital
- || epirubicin / Generic mfg.
Review, Journal: Dendrimer- and polymeric nanoparticle-aptamer bioconjugates as nonviral delivery systems: a new approach in medicine. (Pubmed Central) - Sep 2, 2021
Various anticancer agents have been encapsulated with dendrimers complexing with aptamers, including epirubicin, camptothecin, Bcl-xL short hairpin (sh)RNA, and 5-fluorouracil rhodamine-labeled dextran. Other types of polymeric nanoparticle (NP)-aptamer bioconjugates have also been developed and loaded with Pt(IV) derivatives, to target specific tumor cells.
- ||| epirubicin / Generic mfg.
Clinical, Journal, Adverse events: Hypnosis Sedation Reduces the Duration of Different Side Effects of Cancer Treatments in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. (Pubmed Central) - Aug 28, 2021
Other types of polymeric nanoparticle (NP)-aptamer bioconjugates have also been developed and loaded with Pt(IV) derivatives, to target specific tumor cells. Despite the limitations of this study (lack of randomization and small size) we conclude that hypnosis sedation may exert a role on different side effects of breast cancer treatment in patients receiving neoadjuvant chemotherapy, mainly by reducing their duration.
- || paclitaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy. (Pubmed Central) - Aug 28, 2021
Despite the limitations of this study (lack of randomization and small size) we conclude that hypnosis sedation may exert a role on different side effects of breast cancer treatment in patients receiving neoadjuvant chemotherapy, mainly by reducing their duration. In our cohort of BC patients, a combined treatment with oral myo-inositol + IP6 local application was able to improve local symptoms and quality-of-life related symptoms which represent clinically relevant aspects associated with patient's prognosis.
- | New P2 trial: Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids (clinicaltrials.gov) - Aug 26, 2021
P2, N=33, Not yet recruiting, Sponsor: University Hospital Inselspital, Berne
- || capecitabine / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. (Pubmed Central) - Aug 26, 2021
As the patient had already received 5-FU within the FEC protocol (5-FU 500 mg/m, epirubicin 100 mg/m, and cyclophosphamide 500 mg/m) 10 years ago without experiencing any severe adverse event, no DPD deficiency testing was performed before capecitabine treatment...This case proves that tolerance to low-dose fluoropyrimidines does not preclude DPD deficiency and the occurrence of severe toxicities if higher doses of fluoropyrimidines are used as a second-line treatment. It emphasizes the role of DPD phenotyping testing based on uracilemia in patients scheduled for fluoropyrimidine drugs, even if previous courses with low-dose 5-FU were safely administered.
- | oxaliplatin / Generic mfg., epirubicin / Generic mfg.
New trial: Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 24, 2021
P=N/A, N=89, Completed, Sponsor: Qilu Hospital of Shandong University
- epirubicin / Generic mfg.
Loss of ovarian function in young patients with cancer: prognostic model (Channel 3) - Aug 21, 2021 - Abstract #ESGO2021ESGO_274;
OR: odds ratio; CI: confidence intervals; TaxAC-CMF: Anthracycline and taxane – cyclophosphamide, methotrexate, and fluorouracil; VAI/AI: vincristine, adriamycin and ifosphamide/adriamycin and ifosphamide; EPI-IFO: epirubicin and ifosphamide; ABVD: adriamycin, bleomycine, vinblastine and doxorubicin; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone; FEC: fluorouracil, epirubicine and cyclophosphamide; BEACOPP: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone Conclusion* The model we constructed predicts with good accuracy the individual probability of loss of ovarian function at cancer diagnosis and with every change of treatment. This has a very important implication: the necessity to implement fertility preservation strategies when the risk increases.
- | epirubicin / Generic mfg.
Journal: New use for old drugs: Epirubicin in colorectal cancer. (Pubmed Central) - Aug 20, 2021
This has a very important implication: the necessity to implement fertility preservation strategies when the risk increases. No abstract available
- || Clinical, P2 data, Journal: A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. (Pubmed Central) - Aug 20, 2021
P2
CTX could not, therefore, be recommended for further study. This trial adds to current knowledge of docetaxel combined with platinum and 5-FU: that the combination is associated with increased toxicity and its use should be limited to fit patients in need of a response.
- | cisplatin / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. (Pubmed Central) - Aug 19, 2021
Surgical treatment in well-selected patients should therefore be considered. However, peritoneal recurrence remains frequent despite conversion, urging for a better local control.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC) (Channel 1) - Aug 15, 2021 - Abstract #ESMO2021ESMO_3271;
P3
Pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to neoadjuvant pembro 200 mg Q3W or pbo, both given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide. Neoadjuvant pembro + chemo followed by adjuvant pembro showed a statistically significant and clinically meaningful improvement in EFS compared with neoadjuvant chemotherapy alone in pts with early-stage TNBC.
- | mitomycin / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study. (Pubmed Central) - Aug 14, 2021
High-risk NMIBC patients who experienced BCG shortage had a high risk of bladder cancer recurrence. Clinical trials of alternative treatment strategies and efforts to increase BCG supply are required.
- | epirubicin / Generic mfg.
Journal: In silico structure prediction, molecular docking and dynamic simulation studies on G Protein-Coupled Receptor 116: a novel insight into breast cancer therapy. (Pubmed Central) - Aug 13, 2021
Molecular dynamic simulation results reveal that the interaction was stable throughout the MD simulation. To the best of our prognosis, GPR116 could be the best molecular target for breast cancer drug discovery.
- || Ontruzant (trastuzumab biosimilar) / Merck (MSD), Samsung, AffaMed Therap, Mundipharma, SIBP-01 (trastuzumab biosimilar) / Sinopharm
Clinical, Journal, Real-world evidence: Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). (Pubmed Central) - Aug 13, 2021
To the best of our prognosis, GPR116 could be the best molecular target for breast cancer drug discovery. Real world data on dual blockade with SB3 and pertuzumab in combination with NACT in a nationwide population-based study show a pCR rate comparable to that seen in previous clinical studies.
- | Journal: Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. (Pubmed Central) - Aug 11, 2021
This work is the first comparison of these cardioprotectants and suggests that resveratrol may be a more effective treatment in the prevention of anthracycline induced cardiotoxicity, compared to dexrazoxane and carvedilol. However, further work will be needed in order to decipher the exact mechanism and potential of this drug in the clinic.